Nouscom: Nouscom and MSD sign a clinical trial and supply agreement

immunotherapies has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). The partnerships aims to evaluate Nouscom's wholly-owned lead candidate, NOUS-209, in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 randomized trials versus KEYTRUDA alone in patients with dMMR/MSI-High Metastatic Colorectal Cancer.